Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoblastic sarcoma of the bladder.

J B Forrest, D C Saypol, S E Mills

    The Journal of Urology
    |August 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diagnostic options for early identification and management of interstitial cystitis/painful bladder syndrome.

    International journal of clinical practice·2009
    Same author

    Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia.

    Prostate cancer and prostatic diseases·2002
    Same author

    Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery.

    British journal of anaesthesia·2002
    Same author

    A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.

    Cancer research·2001
    Same author

    Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading.

    The American journal of surgical pathology·2001
    Same author

    Observations on the presentation, diagnosis, and treatment of interstitial cystitis in men.

    Urology·2001
    Same journal

    On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

    The Journal of urology·2026
    Same journal

    Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

    The Journal of urology·2026
    Same journal

    Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

    The Journal of urology·2026
    Same journal

    The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

    The Journal of urology·2026
    Same journal

    Let's Shift the Focus from Death to Life after Fournier's Gangrene.

    The Journal of urology·2026
    Same journal

    Endourology and Nephrolithiasis.

    The Journal of urology·2026
    See all related articles

    This is the first reported case of immunoblastic sarcoma in the bladder, a rare cancer. Early recognition and tailored treatment, including radiotherapy or chemotherapy, are crucial for managing this condition.

    Area of Science:

    • Oncology
    • Uropathology

    Background:

    • Immunoblastic sarcoma is a rare and aggressive non-Hodgkin lymphoma.
    • The bladder is an unusual site for this malignancy, though chronic antigenic stimulation is a known risk factor for various bladder pathologies.

    Observation:

    • This report details the first documented instance of immunoblastic sarcoma originating in the urinary bladder.

    Findings:

    • The case highlights the potential for immunoblastic sarcoma to develop in organs susceptible to chronic inflammation and antigenic exposure.
    • Histopathological confirmation is essential for diagnosing this rare bladder tumor.

    Implications:

    • Urologists and oncologists should consider immunoblastic sarcoma in the differential diagnosis of bladder tumors, especially in patients with risk factors.

    Related Experiment Videos

  • Treatment strategies should be individualized, involving radiotherapy for localized disease and combination chemotherapy for advanced or metastatic cases.